Mersana Therapeutics Inc. [MRSN] fell -36.98% so far this year. What now?


Mersana Therapeutics Inc. [NASDAQ: MRSN] loss -4.16% or -0.17 points to close at $3.92 with a heavy trading volume of 3966070 shares. The company report on April 6, 2022 that Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards consisting of stock options to purchase an aggregate of 51,150 shares of its common stock to four new employees whose employment commenced in March 2022. The awards were granted pursuant to terms and conditions fixed by the Compensation Committee and as an inducement material to each new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).

The option awards have an exercise price of $4.32 per share, which is equal to the closing price of Mersana’s common stock on April 1, 2022. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the date of the grant and the remainder vesting in equal quarterly installments over the following three years, subject to the applicable employee’s continued service with Mersana on each such vesting date. The options are subject to the terms and conditions of Mersana’s 2022 Inducement Stock Incentive Plan and the terms and conditions of a stock option agreement covering each grant.

It opened the trading session at $4.13, the shares rose to $4.23 and dropped to $3.89, the range by which the price of stock traded the whole day. The daily chart for MRSN points out that the company has recorded -53.72% loss over the past six months. However, it is still -11.68% lower than its most recent low trading price.

If we look at the average trading volume of 1.95M shares, MRSN reached to a volume of 3966070 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Mersana Therapeutics Inc. [MRSN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRSN shares is $21.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRSN stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BTIG Research have made an estimate for Mersana Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 15, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on August 30, 2021, representing the official price target for Mersana Therapeutics Inc. stock. Previously, the target price had yet another raise to $18, while Credit Suisse analysts kept a Neutral rating on MRSN stock.

The Average True Range (ATR) for Mersana Therapeutics Inc. is set at 0.36, with the Price to Sales ratio for MRSN stock in the period of the last 12 months amounting to 7014.98. The Price to Book ratio for the last quarter was 2.32.

Trading performance analysis for MRSN stock

Mersana Therapeutics Inc. [MRSN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.47. With this latest performance, MRSN shares dropped by -5.77% in over the last four-week period, additionally sinking by -53.72% over the last 6 months – not to mention a drop of -76.05% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRSN stock in for the last two-week period is set at 44.30, with the RSI for the last a single of trading hit 41.94, and the three-weeks RSI is set at 44.93 for Mersana Therapeutics Inc. [MRSN]. The present Moving Average for the last 50 days of trading for this stock 4.20, while it was recorded at 4.23 for the last single week of trading, and 7.71 for the last 200 days.

Mersana Therapeutics Inc. [MRSN]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Mersana Therapeutics Inc. [MRSN] shares currently have an operating margin of -392693.02. Mersana Therapeutics Inc.’s Net Margin is presently recorded at -395488.37.

Return on Equity for this stock declined to -97.22, with Return on Assets sitting at -70.93.

Mersana Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.00 and a Current Ratio set at 4.00.

An analysis of insider ownership at Mersana Therapeutics Inc. [MRSN]

There are presently around $294 million, or 91.30% of MRSN stock, in the hands of institutional investors. The top three institutional holders of MRSN stocks are: BLACKROCK INC. with ownership of 7,479,229, which is approximately -15.079% of the company’s market cap and around 0.60% of the total institutional ownership; AVORO CAPITAL ADVISORS LLC, holding 6,800,000 shares of the stock with an approximate value of $27.81 million in MRSN stocks shares; and BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, currently with $22.03 million in MRSN stock with ownership of nearly 45.729% of the company’s market capitalization.

Positions in Mersana Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 76 institutional holders increased their position in Mersana Therapeutics Inc. [NASDAQ:MRSN] by around 10,035,293 shares. Additionally, 41 investors decreased positions by around 8,461,764 shares, while 24 investors held positions by with 53,472,970 shares. The mentioned changes placed institutional holdings at 71,970,027 shares, according to the latest SEC report filing. MRSN stock had 30 new institutional investments in for a total of 2,666,720 shares, while 16 institutional investors sold positions of 4,853,959 shares during the same period.